1. Wood E, Hogg RS, Lima V, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.
2. Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JSG. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr. 2005;38(3):289–95.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;365(6):493–505.
4. World Health Organization. Programmatic update: antiretroviral treatment as prevention (TASP) of HIV and TB: executive summary. 2012.
http://apps.who.int//iris/handle/10665/70904
.
5. Robbins GK, Johnson KL, Chang Y, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010;50(5):779–86.